[COVID-19 Vaccination for Cancer Patients: Progress and Preliminary Recommendations].

The pandemic of coronavirus disease 2019 (COVID-19) has had a serious impact on global health. COVID-19 vaccines may be one of the most effective measure to end the pandemic. High infection risk and higher serious incident and mortality rates have been shown in cancer patients with COVID-19. Therefore, cancer patients should be the priority group for COVID-19 prevention. Until now, data of COVID-19 vaccination for cancer patients is lacking. We review the interim data of safety and immune-efficacy of COVID-19 vaccination in cancer patients based on the latest studies. Due to the complicated immune systems of cancer patients caused by the malignancy and anticancer treatments, we proposed preliminary specific COVID-19 vaccination recommendations for cancer patients with different anticancer treatments and at different stages of the disease. Preventing COVID-19 with vaccinations for cancer patients is crucial, and we call for more large-scale clinical trials and real-world studies, for further COVID-19 vaccination recommendations development.
.

[1]  E. Woo,et al.  US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. , 2021, JAMA.

[2]  A. Wells,et al.  Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients , 2021, medRxiv.

[3]  C. Cogle,et al.  Vaccine Enthusiasm and Hesitancy in Cancer Patients and the Impact of a Webinar , 2021, Healthcare.

[4]  G. Pravettoni,et al.  Current Perspectives: SARS-CoV-2 vaccines for cancer patients: a call to action , 2021, European Journal of Cancer.

[5]  R. Houot,et al.  SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC) , 2021, European Journal of Cancer.

[6]  E. D. de Vries,et al.  The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate , 2021, Annals of Oncology.

[7]  E. Chamorey,et al.  Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey , 2021, Annals of Oncology.

[8]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[9]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[10]  Katie M. Campbell,et al.  Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. , 2020, Cancer discovery.

[11]  B. Keam,et al.  Cell-Mediated Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors. , 2020, The Journal of infectious diseases.

[12]  D. Kerr,et al.  COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.

[13]  M. Santillana,et al.  Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.

[14]  R. Bollag,et al.  Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[15]  C. Flowers,et al.  Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Leibovici,et al.  Influenza vaccines in immunosuppressed adults with cancer. , 2018, The Cochrane database of systematic reviews.